REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 500 participants.

Also called NCT07853716

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
  • Avania Registry lists this organization as a collaborator
  • HeartFlow, Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07853716
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07853716. Randomized; no masking; primary purpose prevention. Start 2026-11 (anticipated); primary completion 2029-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care
Acronym
REFINE-CAC
Intervention (Device)
Heartflow Analysis
Lead sponsor
HeartFlow, Inc. (class: industry)
Collaborator
Avania (class: industry)

Record details

Record id
cardio:ct-nct07853716
Content hash
4ee7ae81e5ad7d50b5364832991cd63749f9100a99e43cdf41153ceb4d143db6